were found at higher frequencies in psychiatric patients than in healthy controls, BDV is suspected to cause psychiatric disorders in humans. However, the human origin of these viruses has recently been questioned. 12 To diagnose BDV infections, sera are usually analyzed for antiviral antibodies by indirect immunofluorescence (IFA) on virus-infected cells.
About 6% of psychiatric patients in the Gü nzburg clinic were previously found to test positive for BDV antibodies by IFA. 14 The twenty-five most strongly reacting sera of this collection were used in the present study (Table 1) . Their IFA titers ranged from 1:20 to 1:640 when BDV-infected MDCK cells were used for analysis. Two sera with exceptionally high antibody titers (No. 175 and No. 321) were selected for more detailed characterization. They both also tested positive when BDV-infected cells from other species were used for analysis, although the titers were lower under these alternative assay conditions (Table 1 ). In BDVinfected rat C6 cells ( Figure 1A and C) as well as in the other cells (data not shown), these sera specifically stained distinct nuclear inclusion bodies which were also stained by sera of BDV-infected animals ( Figure  1G and I). These nuclear structures, which presumably represent aggregates of viral ribonucleoprotein complexes, were not stained in uninfected cells (data not shown). To evaluate antigen specificity, the sera were incubated with agarose beads loaded with either BDVp40, BDVp24, a mixture of both or with an irrel- Figure 1 Testing human and animal sera for BDV-specific antibodies by IFA on infected C6 cells (C6-BDV) or p24-transfected Vero cells (Vero-p24) in the presence or absence of urea. Assay conditions were as described in Materials and Methods. The various sera were used at dilutions four-to eight-fold below their end titers. Note that reactive sera specifically stained a few distinct intranuclear dots in C6-BDV cells, whereas they stained the whole nucleoplasma of Vero-p24 cells. evant control protein. After depletion, the sera were assayed for loss of reactivity by standard IFA on BDVinfected C6 cells. Agarose beads carrying both BDV antigens efficiently removed the reactivity from patient serum No. 175 and No. 321 as well as from animal sera, whereas beads carrying the irrelevant control protein did not (data not shown). Beads carrying only BDVp24 depleted the human sera remarkably well, whereas beads carrying only BDVp40 were much less effective (data not shown). To verify that the viral phosphoprotein p24 was recognized by reactive human sera, we performed IFA on Vero cells transiently transfected with a BDVp24 expression construct. Specific staining of the nucleoplasma of transfected cells was observed when sera No. 175 and No. 321 were used ( Figure 1L and N). Of the other human sera with high antibody titers on BDV-infected MDCK cells, No. 335 similarly stained p24-expressing Vero cells at a dilution of 1:10, whereas sera Nos 241, 250, 268, 283 and a negative control serum did not (data not shown). Serum of a healthy Japanese blood donor (No. 130) that tested positive on BDV-infected C6 cells ( Figure 1E ) also strongly stained the nucleoplasma of p24-expressing Vero cells ( Figure 1P ). Due to the fact that BDVp40 expressed from cDNA constructs was present in the cytoplasm and nucleus of transfected Vero cells, an IFA test system designed to detect antibodies with specificity for this viral protein exhibited only low sensitivity, which greatly limited its value. Some animal sera with high antibody titers reacted positive in this p40 assay, but all human sera scored negative (data not shown).
Antibodies generated during the course of an immune response greatly change avidity for the inducing antigen. Low-avidity IgG antibodies are produced soon after the first encounter with the immunogen, while high-avidity antibodies are typically produced by memory B cells at late stages of the immune response. IgG avidity determination is frequently employed to distinguish between primary viral infection, re-infection and reactivation of latent viruses. 15 Avidity determination can further help to differentiate between antibodies that recognize their proper antigen and antibodies that recognize related antigens as a result of cross-reactivity: 16, 17 cross-reactive antibodies typically exhibit a low-avidity phenotype for the alternative targets. Reactive antibodies in sera of BDVinfected mice and rabbits were not eluted from the viral targets during a brief wash with buffer containing 3 M urea, indicating that they exhibited high avidity (data not shown). Similarly, antibodies in serum of a BDV-infected monkey ( Figure 1H ) or a horse with naturally acquired Borna disease ( Figure 1K ) remained bound to viral antigen when exposed to buffer containing 3 M urea. By contrast, reactive antibodies in the sera of psychiatric patients No. 321 ( Figure 1B) and No. 175 ( Figure 1D ) were readily eluted under these conditions. End point dilution analysis showed that the titers of both sera dropped 16-fold when the 3 M urea wash step was included (Table 1) . By contrast, serum antibody titers of horses with Borna disease did not drop noticeably under these conditions (Table 2 ). When the 3 M urea washing procedure was used to characterize 21 additional reactive sera from the Gü nzburg patient collection, we measured strongly decreased antibody titers which were frequently below the detection limit of the assay ( Table 1 ), indicating that they all contained antibodies with low avidity for BDV antigens. Furthermore, serum No. 130 from the Japanese blood donor was also found to contain reactive antibodies that were sensitive to urea treatment ( Figure 1F ; Table 1 Figure 1Q) , whereas large numbers of strongly stained cells were present on slides treated with serum from the BDV-infected monkey ( Figure 1S ) or horse ( Figure 1U ). Multiple archival serum samples were available for analysis from two positive patients of our cohort. Antibodies with reactivity for BDV antigens persisted for more than 3 years in patient UB, and for more than 7 years in patient JH (Table 1) . Importantly, the low-avidity phenotype of these antibodies did not change during the whole observation periods. Both sera contained IgG that recognized Epstein-Barr virus capsid antigens with high avidity (data not shown), demonstrating that the patients had no general deficit of antibody maturation. By contrast, sera from horses with Borna disease contained antibodies that resisted 3 M urea even at the earliest times after seroconversion ( Table 2 ). The notion that BDV infections might be associated with human psychiatric disorders is mainly based on previous observations that sera of psychiatric patients, but not of healthy controls, frequently contain antibodies that recognize BDV antigens.
1,9,10,14 The goal of this study was to characterize the specificity of these antibodies in more detail. By employing matrix-immobilized recombinant viral antigens for serum depletion experiments and standard IFA on BDV-infected cells for analysis, we demonstrated that reactive human sera exhibit specificity for BDVp24. This result was confirmed on transfected Vero cells that overexpress BDVp24. The most striking difference between reactive human and animal sera was, however, that all 26 human sera characterized here failed to bind BDV antigen with high avidity. By contrast, all experimentally infected animals and all naturally infected horses with autopsy-confirmed Borna disease that we tested to date contained serum antibodies that resisted 3 M urea. It should be noted that the investigated human sera represent a highly selected collection of top-scoring samples originally identified by screening about 15 000 patients from various departments of the Gü nzburg clinic and 200 healthy blood donors from Japan, respectively. It thus seems likely that human antibodies reactive to BDV antigens in general are not selected toward high avidity. However, it remains possible that a few exceptional 'truly positive' samples might remain hidden in the large panel of reactive human sera with low BDV-specific antibody titers. Due to the limited sensitivity of our IFA test system, these low titer sera did not yield meaningful results in avidity tests. Human antibodies with reactivity for BDV antigens were observed by other groups in ELISA, ECLIA or Western blot assays. [18] [19] [20] [21] [22] It is of great interest to know whether these interactions are also of low avidity. In our laboratory, these alternative assay systems worked well only with animal sera but failed to yield reliable results with human sera. Avidity studies of reactive human IgG using these assay systems thus remained non-conclusive.
As we found that low-avidity antibodies with reactivity for BDV antigens persisted for several years in retrospective serum samples from two psychiatric patients, it seems extremely unlikely that their presence indicates recent infection with BDV. Interestingly, infected horses contained high-avidity antibodies at very early times after seroconversion, further stressing the imperfect state of reactive human antibodies. The long persistence of low-avidity antibodies in human sera thus seems to indicate cross-reactivity. Given the very limited sequence divergence between standard animal BDV and strains of BDV believed to originate from humans, 1 it is very unlikely that these viruses can induce grossly different antibody responses. In fact, all our attempts to observe such differences between sera of mice infected with strains V and He/80 were unsuccessful. We further failed to detect such differences when the cells used for IFA were infected with various strains of BDV, including No/98 which represents a BDV field isolate with rather remote relationship to classical strains. 23 It is clear from these observations that the observed cross-reactivity of human antibodies involves an immunogen with far less similar antigenic properties. We cannot exclude the alternative possibility that the apparent anomalies in the observed serum antibody responses simply reflect our limited understanding of human BDV infections, which were suggested to involve only low levels of viral antigen 5, 6, 8 and, consequently, might result in less robust antibody responses.
It is remarkable that virtually all available reports on BDV-specific antibodies in humans agree on the notion that such antibodies occur at enhanced frequency in psychiatric patients (see Staeheli et al for a review 1 ). BDV seroprevalence was further found to increase with age in non-psychiatric controls. 24 These observations are compatible with the view that a microbial infection prompted the critical immune response. The nature of the immunogen which induces BDV-reactive antibodies in humans remains unknown.
Our findings have important consequences for the correct interpretation of serological data that address the epidemiology of BDV. Since animals with confirmed BDV infections always contained serum antibodies with high avidity for viral antigens even at very early times after seroconversion, we believe that antibodies with low avidity to BDV antigens have little diagnostic significance as they could have been induced by an immunogen which is distinct from BDV. Our data thus question the predictive value of serological tests presently used for the diagnosis of primary and chronic BDV infections of humans and farm animals, and they strongly suggest that additional tests should be introduced for confirmation. Our results call for a careful re-evaluation of previous epidemiological studies which indicated that BDV infections of animals as well as humans might occur worldwide (see Staeheli et al for a review 1 ).
Methods
IFA was performed on fixed and permeabilized cells persistently infected with BDV strain He/80 as previously described. 9, 13 Rat C6, canine MDCK, monkey Vero and human Oligo cells were used for these experiments. To check whether the binding of reactive IgG to viral proteins had occurred with high avidity, we adopted techniques previously established for EpsteinBarr virus serology. 25 Briefly, slides with fixed cells were incubated with test serum as usual, but they were then subjected to one additional washing step for 3 min at room temperature with phosphate buffered saline (PBS) containing 3 M urea, followed by several washing steps with PBS and incubation with secondary antibodies. To determine antigen specificity, 200-l samples of diluted sera were incubated overnight at 4°C with 100 l of packed nickel chelate agarose beads loaded with 5 g of histidine-tagged recombinant BDVp24 (phosphoprotein), BDVp40 (nucleoprotein), a mixture of these two viral antigens or an irrelevant histidine-tagged control protein (hGBP1). Treated sera were then analyzed for loss of reactivity on BDVinfected cells as described above. Transient transfections of monkey Vero cells with cDNA expression constructs encoding BDVp24 or BDVp40 were performed using Effectene (Qiagen, Hilden, Germany). These constructs were generated by inserting the appropriate BDV cDNAs 26 into plasmid pTRE (Clontech, Heidelberg, Germany). At 40 h post transfection, the cells were fixed, permeabilized and subjected to IFA as described above.
